SGLT2 inhibitors and GLP-1 receptor agonists are employed as therapeutic options for individuals with T2DM to lower blood glucose levels, and they offer supplementary advantages such as weight loss and decreased blood pressure. Findings from CV outcome trials have underscored that these medications provide protective benefits against major CV disease in those with established ASCVD, reduce the risk of admission to hospital for heart failure, and reduce mortality. This evidence concerns the gene SLC5A2 and heart failure.